Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs.
about
Microvesicles as a potential biomarker of neoplastic diseases and their role in development and progression of neoplasmmicroRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessmentNon-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and MouseIdentification of microRNAs in Macaca fascicularis (Cynomolgus Monkey) by Homology Search and Experimental Validation by Small RNA-Seq and RT-qPCR Using Kidney Cortex TissuesPaving the Route to Plasma miR-208a-3p as an Acute Cardiac Injury Biomarker: Preclinical Rat Data Supports Its Use in Drug Safety Assessment.The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer.Microvesicles as potential ovarian cancer biomarkers.The current status of biomarkers for predicting toxicity.Safety biomarkers in preclinical development: translational potential.Circulating biomarkers for gliomas.Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents.Androgen Stimulation of PCA3 and miR-141 and Their Release from Prostate Cancer Cells.The new revolution in toxicology: the good, the bad, and the ugly.Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance.Evaluation of miR-216a and miR-217 as Potential Biomarkers of Acute Exocrine Pancreatic Toxicity in Rats.Current trends in in silico, in vitro toxicology, and safety biomarkers in early drug development.
P2860
Q26768704-55905A92-C95B-41CB-ADBF-5B1399C49B4CQ26778918-126FCB0F-AE04-4320-B007-BCE1A47A237DQ28079801-D7CAAD5E-733D-47DE-86C6-7CBB4EE111E5Q28550919-21C58BFD-6C3D-4FFD-8F62-65527FC955A8Q31004210-39857C51-BB57-495F-8426-307F844C52D8Q33691489-BB19E6EE-315C-4A4C-9FDE-073B5A8A1DBFQ36635032-F4D21BBA-84A0-4D8F-8074-1AF0E6101195Q37408227-AE242F8A-EB63-4B85-8ED8-399C04540F45Q38148980-F60B9A87-E4AC-46DD-AAF6-984221EC0D70Q38586617-55CA4DE3-E571-455F-B8AE-9677F0BF7189Q39201920-207033D2-3532-408A-8341-AF12787FAF18Q40437431-977B2BCE-9FA3-4A6E-B577-7A168B41370FQ41808633-C170784A-160A-4784-88BE-EFE38BA8B5A6Q45421942-EF20A4F0-EE8C-4B38-A7F6-1A10DA2A74BBQ45967235-5368B191-6A1D-4AE9-A4AF-56FC2C3A69A4Q46788854-28A30FA3-2E48-43C0-A5F4-360A45AF02FDQ47434464-625016B7-DC30-4444-896F-8A21D6AD3144
P2860
Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs.
@en
type
label
Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs.
@en
prefLabel
Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs.
@en
P2093
P2860
P356
P1476
Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs.
@en
P2093
Bruce E Leroy
Igor Mikaelian
Marshall Scicchitano
Odete Mendes
Roberta A Thomas
P2860
P356
10.1177/0192623312448939
P407
P577
2012-06-01T00:00:00Z